Mrunal Monica Phadnis
About Mrunal Monica Phadnis
Title and Role in Clinical Operations
Monica Phadnis holds a prominent role in Clinical Operations with over 17 years of experience in oncology clinical development. Her career spans across diverse geographical regions including North America, Europe, Asia, and Australia. She is widely recognized for her contribution to the Precision Medicine TEPMETKO® Program and her advancements in research leading to the FDA granting 'Breakthrough Therapy Designation' for Tepotinib in the NSCLC program.
Experience in Oncology Clinical Development
Monica Phadnis has an extensive background in oncology clinical development, having started her career as a Program Manager at Selventa. She was responsible for discovering genetic pathways for drug-resistant solid tumors. Subsequent roles include leading the Breast and Thoracic Oncology Unit at Memorial Sloan-Kettering as a Portfolio Manager, where she managed a significant portfolio of over 75 clinical trials and a team of over 30 staff members.
Achievements and Leadership Awards
Monica Phadnis is a recipient of multiple leadership awards for her innovative solutions in the clinical trial life cycle. Her ability to create and execute customized strategies has led to the timely achievement of global milestones. She has been pivotal to advancing research liquid biopsies and has made notable contributions as the New York State leader for the Cancer and Leukemia Group B (CALGB) national program.
Educational Background
Monica Phadnis holds a Bachelor’s degree in Mathematics from the University of Mumbai. She further enhanced her academic credentials by completing a Pre-Medicine Diploma from Harvard University, which equipped her with a solid foundation necessary for her successful career in clinical operations and oncology.
Industry Contributions and Speaking Engagements
Monica Phadnis has made substantial contributions to the oncology field through her frequent presentations at the American Society of Clinical Oncology (ASCO) and her engagements as a guest speaker and panelist at various oncology conferences. Her thought leadership and expertise are widely recognized and valued in the industry.